Table 3.
Antihypertensive medication use during pregnancy, among women who reported hypertension during the index pregnancy, and risk of SGA, by type of hypertension, National Birth Defects Prevention Study, 2006-2011. The reference group for all logistic regression models is normotensive women who did not report taking an antihypertensive medication during pregnancy. Values for SGA and Non-SGA columns are n (%).
| Exposure Groupa | SGA (n=505) |
Non-SGA (n=4,122) |
OR (95% CI) b | AOR (95% CI)c |
|---|---|---|---|---|
| Any antihypertensive medication use | ||||
| Among women with pregnancy related hypertension | 5 (1.0) | 28 (0.7) | 1.51 (0.58, 3.93) | 2.19 (0.81, 5.92) |
| Among women with chronic hypertension | 5 (1.0) | 38 (0.9) | 1.11 (0.44, 2.84) | 0.84 (0.25, 2.83) |
| Untreated hypertension | ||||
| Among women with pregnancy related hypertension | 44 (8.7) | 252 (6.1) | 1.47 (1.05, 2.06) | 1.45 (1.00, 2.09) |
| Among women with chronic hypertension | 1 (0.2) | 15 (0.4) | - | - |
| No hypertension (reference) | 450 (89.1) | 3,789 (91.9) | 1.00 | 1.00 |
Excludes n=12 women (3 SGA, 9 non-SGA) who reported both chronic and pregnancy related hypertension during the index pregnancy.
For groups with <5 exposed SGA births, we calculated the exact 95% CI.
Adjusted for maternal race/ethnicity, maternal age at delivery, maternal prepregnancy BMI, late pregnancy smoking, early pregnancy folic acid supplement use, and study site.